ConforMIS, Inc. (CFMS) Shares Bought by Geode Capital Management LLC
Geode Capital Management LLC raised its stake in shares of ConforMIS, Inc. (NASDAQ:CFMS) by 4.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 329,058 shares of the medical instruments supplier’s stock after buying an additional 13,731 shares during the period. Geode Capital Management LLC owned approximately 0.75% of ConforMIS worth $1,717,000 as of its most recent filing with the SEC.
Several other institutional investors have also added to or reduced their stakes in CFMS. Wellington Management Group LLP boosted its position in ConforMIS by 2.4% in the first quarter. Wellington Management Group LLP now owns 5,644,206 shares of the medical instruments supplier’s stock valued at $29,463,000 after buying an additional 132,211 shares during the period. American International Group Inc. raised its stake in ConforMIS by 7.0% in the first quarter. American International Group Inc. now owns 22,009 shares of the medical instruments supplier’s stock valued at $115,000 after buying an additional 1,448 shares in the last quarter. Marathon Capital Management purchased a new stake in ConforMIS during the first quarter valued at about $1,052,000. Wells Fargo & Company MN raised its stake in ConforMIS by 1.8% in the first quarter. Wells Fargo & Company MN now owns 53,930 shares of the medical instruments supplier’s stock valued at $282,000 after buying an additional 935 shares in the last quarter. Finally, Creative Planning purchased a new stake in ConforMIS during the first quarter valued at about $236,000. Institutional investors own 34.05% of the company’s stock.
ConforMIS, Inc. (CFMS) traded up 4.43% during midday trading on Thursday, hitting $3.77. The company had a trading volume of 52,584 shares. The company’s 50 day moving average is $4.14 and its 200-day moving average is $4.87. ConforMIS, Inc. has a one year low of $3.22 and a one year high of $10.93. The company’s market cap is $169.03 million.
ConforMIS (NASDAQ:CFMS) last issued its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.08. The business had revenue of $18.50 million for the quarter, compared to the consensus estimate of $19.34 million. ConforMIS had a negative return on equity of 66.61% and a negative net margin of 72.87%. The firm’s quarterly revenue was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.34) earnings per share. On average, equities analysts predict that ConforMIS, Inc. will post ($1.30) EPS for the current year.
CFMS has been the topic of several research reports. B. Riley reissued a “buy” rating and set a $7.50 price target on shares of ConforMIS in a research report on Thursday, May 11th. Canaccord Genuity set a $8.00 price target on ConforMIS and gave the company a “hold” rating in a research report on Thursday, May 11th. Oppenheimer Holdings, Inc. set a $9.00 price target on ConforMIS and gave the company a “buy” rating in a research report on Wednesday, May 10th. Zacks Investment Research raised ConforMIS from a “sell” rating to a “hold” rating in a research report on Monday, May 15th. Finally, BTIG Research initiated coverage on ConforMIS in a research report on Tuesday, June 20th. They set a “neutral” rating on the stock. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $7.75.
In related news, Director Bradley Langdale sold 6,722 shares of the stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $4.30, for a total transaction of $28,904.60. Following the sale, the director now owns 26,533 shares of the company’s stock, valued at $114,091.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 9.55% of the company’s stock.
ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.
Receive News & Stock Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related stocks with our FREE daily email newsletter.